PPD’s Post

The journey from scientific discovery to commercial success in cell and gene therapy is full of challenges. These challenges were the focus of a recent panel at the #PharmaLifeSciences2024: Advancements in Cell and Gene Therapy virtual summit, featuring Likarda CEO, Dr. Stella K. Vnook. Key topics included scaling production, patient engagement, and navigating regulatory hurdles—along with strategies to overcome them. Thank you to TechTarget for summarizing this insightful discussion, which you can read here: https://lnkd.in/gpreEJes #CellTherapy #GeneTherapy #HealthcareInnovation #Biotech

Interesting article regarding the future of cell and gene therapies and the cold chain logistics they require. Our VP of Cell and Gene Therapies Emilio Frattaruolo, CPPL is always happy to discuss your specific requirements!

Insightful perspective from one of the industries leading experts in this field.

The advent of cell and gene therapies is a promising shift in the healthcare landscape, yet it isn't without its unique challenges. From intricate manufacturing phases to regulatory complexities, these obstacles must be navigated for its full potential to be realized. In a recent interview with Clinical Leader, Roger Palframan, Head of US Research UCB, explores these issues - offering insight into how we can overcome them. Read it now: https://lnkd.in/dVvGxRE7 #CellAndGeneTherapy #HealthcareInnovation

The future of healthcare is on the horizon, and cell and gene therapies are poised to play a transformative role. But the question remains: when will this exciting potential become a reality for patients? To explore this critical topic, industry leaders and healthcare stakeholders are gathering today and tomorrow (April 15th-16th) at the 2nd Cell and Gene Therapy Summit, organised by The Economist. James Rutley, Autolomous Head of Business Development, is attending the summit and is eager to discuss the challenges of introducing advanced therapies into the mainstream and how we can tackle them together. We are committed to collaborating with fellow leaders to accelerate advancements in the CGT industry. Our ultimate goal? Ensuring broader patient access to these life-saving therapies. #networking #CellandGeneTherapy #PatientAccess

Don't forget to sign up for the Biophysical Summit hosted by Applied Photophysics and KBI Biopharma! 🏔 This summit will highlight some of the latest analytical techniques for developing and characterizing protein and gene therapies. Come with your questions and learn how companies tackle the characterization of novel modalities! Register here: https://bit.ly/3TxZawo #BiophysicalSummit #KBI #AppliedPhotophysics

Join our webinar next week to learn about development of a #nonviral CAR-T manufacturing process. #celltherap #cellengineering #CRISPR

It was a pleasure to sit down with Fierce Biotech to share my thoughts on the state of the cell and gene industry and the pivotal role that the cold chain is playing in it's progression. Watch the video below: #cellandgene #SupplyChainSolutions #ColdChain #TemperatureControl #PharmaSupplyChain #Logistics #Sustainability #Cryo

If you are not watching it right now, register and access the recordings later, this is definitely worth listening to. Fascinating topics. Valuable insights and business-minded outlook. Each session highlights the current landscape, gets right to the heart of the existing issues and identifies the most promising ways forward.

How do you choose the right CDMO for gene engineering? David Hermanson, Director of Cell and Gene Therapy Applications at Bio-Techne, participated in a dynamic panel, hosted by ISCT, to discuss this topic. Together with industry experts Jeff Liter, Luminary Therapeutics and Farzin Farzeneh, Virocell, they explored the critical factors to consider when sourcing a CDMO. Discover key insights from their conversation in our latest blog post, where we also explore the use of viral and non-viral methods. Read more now: bit.ly/4cYQuX8